TY - JOUR
T1 - Potential Neuroprotective Effect of Cannabinoids in COVID-19 Patients
AU - Cortes-Altamirano, José Luis
AU - Yáñez-Pizaña, Ariadna
AU - Reyes-Long, Samuel
AU - Angélica, González Maciel
AU - Bandala, Cindy
AU - Bonilla-Jaime, Herlinda
AU - Alfaro-Rodríguez, Alfonso
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/6
Y1 - 2022/6
N2 - The global pandemic caused by the SARS-CoV-2 virus began in early 2020 and is still present. The respiratory symptoms caused by COVID-19 are well established. However, neurological manifestations that may result from direct or indirect neurological damage after SARS-CoV-2 infection have been reported frequently. The main proposed pathophysiological processes leading to neurological damage in COVID-19 are cerebrovascular disease and indirect inflammatory/ autoimmune origin mechanisms. A growing number of studies confirm that neuroprotective measures should be maintained in COVID-19 patients. On the other hand, cannabinoids have been the subject of various studies that propose them as potentially promising drugs in chronic neurodegenerative diseases due to their powerful neuroprotective potential. In this review, we addresses the possible mechanism of action of cannabinoids as a neuroprotective treatment in patients infected by SARS-CoV-2. The endocannabinoid system is found in multiple systems within the body, including the immune system. Its activation can lead to beneficial results, such as a decrease in viral entry, a reduction of viral replication, and a reduction of pro-inflammatory cytokines such as IL-2, IL-4, IL-6, IL-12, TNF-α, or IFN-c through CB2R expression induced during inflammation by SARS-CoV-2 infection in the central nervous system.
AB - The global pandemic caused by the SARS-CoV-2 virus began in early 2020 and is still present. The respiratory symptoms caused by COVID-19 are well established. However, neurological manifestations that may result from direct or indirect neurological damage after SARS-CoV-2 infection have been reported frequently. The main proposed pathophysiological processes leading to neurological damage in COVID-19 are cerebrovascular disease and indirect inflammatory/ autoimmune origin mechanisms. A growing number of studies confirm that neuroprotective measures should be maintained in COVID-19 patients. On the other hand, cannabinoids have been the subject of various studies that propose them as potentially promising drugs in chronic neurodegenerative diseases due to their powerful neuroprotective potential. In this review, we addresses the possible mechanism of action of cannabinoids as a neuroprotective treatment in patients infected by SARS-CoV-2. The endocannabinoid system is found in multiple systems within the body, including the immune system. Its activation can lead to beneficial results, such as a decrease in viral entry, a reduction of viral replication, and a reduction of pro-inflammatory cytokines such as IL-2, IL-4, IL-6, IL-12, TNF-α, or IFN-c through CB2R expression induced during inflammation by SARS-CoV-2 infection in the central nervous system.
KW - CB1
KW - CB2
KW - COVID-19
KW - Cannabinoids
KW - Neuroprotection
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85135166649&partnerID=8YFLogxK
U2 - 10.2174/1568026622666220405143003
DO - 10.2174/1568026622666220405143003
M3 - Estudio breve
C2 - 35382723
AN - SCOPUS:85135166649
SN - 1568-0266
VL - 22
SP - 1326
EP - 1345
JO - Current Topics in Medicinal Chemistry
JF - Current Topics in Medicinal Chemistry
IS - 16
ER -